Financial Performance - The company reported a revenue of CNY 136.87 million for Q1 2023, representing a 19.79% increase compared to CNY 114.26 million in the same period last year[4]. - Net profit attributable to shareholders decreased by 15.80% to CNY 45.05 million from CNY 53.50 million year-on-year[4]. - Revenue from non-COVID-19 prevention products was CNY 119.35 million, an increase of 32.37% year-on-year, while revenue from COVID-19 prevention products fell by 27.30% to CNY 17.52 million[4]. - Total operating revenue for Q1 2023 reached ¥136,865,462.92, an increase of 19.8% compared to ¥114,258,131.97 in the same period last year[15]. - Net profit for Q1 2023 was ¥42,917,350.22, a decrease of 19.6% from ¥53,416,447.82 in Q1 2022[16]. - Total comprehensive income for the first quarter was CNY 44,761,276.15, a decrease of 16.5% compared to CNY 53,404,116.95 in the previous period[17]. Cash Flow and Investments - The net cash flow from operating activities increased by 19.13% to CNY 43.68 million compared to CNY 36.66 million in the previous year[4]. - Cash inflow from operating activities totaled CNY 140,542,625.73, an increase of 18.6% compared to CNY 118,501,065.66[19]. - Cash outflow from operating activities rose to CNY 96,863,467.12, up 18.4% from CNY 81,836,230.28[19]. - Net cash flow from investing activities was negative at CNY -103,630,241.42, an improvement from CNY -708,628,997.78 in the previous period[20]. - The company reported cash inflow from investment activities of CNY 677,746,001.59, down 21.1% from CNY 859,338,417.54[20]. - Total cash outflow from investing activities was CNY 781,376,243.01, a decrease of 50.1% compared to CNY 1,567,967,415.32[20]. - Cash and cash equivalents at the end of the period decreased to CNY 373,088,562.49 from CNY 852,129,668.04, a decline of 56.2%[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,436[8]. - The largest shareholder, Chen Yiding, holds 23.53% of the shares, totaling 18,827,168 shares[8]. - Shareholders' equity attributable to shareholders increased by 1.94% to CNY 2.61 billion from CNY 2.56 billion at the end of the previous year[4]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2.77 billion, a 1.10% increase from CNY 2.74 billion at the end of the previous year[4]. - Total assets as of the end of Q1 2023 were ¥2,766,184,307.54, compared to ¥2,735,960,236.60 at the beginning of the year, indicating a slight increase of 1.1%[13]. - Total liabilities decreased to ¥149,891,559.21 from ¥167,253,156.96, a reduction of 10.4%[13]. - The company's equity attributable to shareholders increased to ¥2,612,922,271.33 from ¥2,563,204,428.74, reflecting a growth of 1.9%[13]. Research and Development - Research and development expenses increased to ¥28,785,836.45, compared to ¥22,542,358.36 in the previous year, reflecting a growth of 27.6%[16]. Earnings Per Share - Basic earnings per share decreased by 15.79% to CNY 0.3754 from CNY 0.4458 in the same period last year[4]. - Basic earnings per share decreased to CNY 0.3754 from CNY 0.4458, reflecting a decline of 15.5%[17]. Other Information - The company received government subsidies amounting to CNY 392,391.70 during the reporting period[6]. - Other comprehensive income after tax for Q1 2023 was ¥1,843,925.93, compared to a loss of ¥12,330.87 in the same period last year[16]. - The first quarter report was not audited[21].

Financial Performance - The company's operating revenue for 2022 was approximately ¥474.43 million, representing a 23.23% increase compared to ¥384.99 million in 2021[20]. - The net profit attributable to shareholders for 2022 was approximately ¥203.73 million, an increase of 16.94% from ¥174.21 million in 2021[20]. - The net cash flow from operating activities increased by 46.51% to approximately ¥202.19 million in 2022, up from ¥138.01 million in 2021[20]. - The basic earnings per share for 2022 was ¥1.70, a slight increase of 0.71% compared to ¥1.69 in 2021[20]. - Total assets as of the end of 2022 were approximately ¥2.74 billion, reflecting a 7.51% increase from ¥2.54 billion at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥2.56 billion, up 3.90% from ¥2.47 billion at the end of 2021[20]. - The company reported a weighted average return on equity of 8.13% for 2022, a decrease of 19.28% from 27.41% in 2021[20]. - The net profit after deducting non-recurring gains and losses for 2022 was approximately ¥183.29 million, an increase of 11.69% from ¥164.11 million in 2021[20]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of ¥15 per 10 shares, totaling approximately ¥12 million based on the total share capital of 80 million shares[4]. - The company distributed a cash dividend of RMB 15.00 per 10 shares, totaling RMB 120,000,000, which accounted for 100% of the total profit distribution[175]. Market and Industry Outlook - The global biopharmaceutical market is projected to grow from USD 286.4 billion in 2019 to USD 456.7 billion by 2024, with a compound annual growth rate (CAGR) of 9.8%[31]. - China's biopharmaceutical market is expected to expand from USD 48 billion in 2019 to USD 109.6 billion by 2024, achieving a CAGR of 18.0%[31]. - The global bioreagent market is anticipated to grow from USD 12.8 billion in 2015 to USD 24.6 billion by 2024, with a CAGR of 7.1%[33]. - The recombinant protein research reagent market is expected to increase from USD 0.5 billion in 2015 to USD 1.5 billion by 2024, with a CAGR of 13.6%[36]. - The CAR-T market is projected to reach USD 6.6 billion by 2024, with a remarkable CAGR of 55.0% from 2019 to 2024[36]. Product Development and Innovation - The company has established R&D centers in China and the U.S., focusing on innovative technologies such as membrane protein expression and purification, and data-driven optimization techniques[41]. - The company has developed multiple innovative products, including high-activity CD19 target proteins and COVID-19 spike proteins, tailored to complex drug development needs[42]. - The company focuses on high-quality recombinant proteins for targeted therapies and immunotherapies, addressing the needs of biopharmaceutical development[50]. - The company is actively involved in the development of vaccines and diagnostic reagents, particularly for viral proteins related to COVID-19[49]. - The company has developed over 2800 types of recombinant proteins to support molecular interaction analysis services, which are crucial for drug development and production quality monitoring[52]. Research and Development Investment - The company invested CNY 113.85 million in R&D, marking a 91.17% increase, and expanded its R&D team to 189 personnel, a growth of 54.92%[75]. - The company increased its R&D investment to approximately ¥113.85 million in 2022, representing 24.00% of its operating revenue, up from 15.47% in 2021[94]. - The number of R&D personnel rose to 189 in 2022, a 54.92% increase from 122 in 2021, with a notable increase in personnel holding master's and doctoral degrees[94]. Operational Efficiency and Cost Management - The company is optimizing production processes and exploring new technologies, including gene editing and automation, to improve efficiency and meet market demands[79]. - The company plans to enhance its global R&D presence by establishing new laboratories in Europe and expanding its technical platforms for protein preparation and clinical sample analysis[123]. - The company will focus on strengthening its brand marketing and expanding its sales channels to increase market share in the Asia-Pacific, North America, and Europe regions[124]. Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operation from its controlling shareholder[134]. - The company has held five shareholder meetings during the reporting period, with all resolutions passed legally and effectively[134]. - The company emphasizes transparency and timely information disclosure, adhering to regulations and utilizing multiple communication channels with investors[136]. - The company has established a complete organizational structure, ensuring effective operation of internal governance bodies without interference from the controlling shareholder[138]. Environmental Responsibility - The company completed the environmental impact assessment and received approval for its production site, with the wastewater treatment facilities installed to meet regulatory standards[190]. - The company has implemented strict environmental management measures and pollution control, adhering to multiple environmental laws and regulations[189]. - The company invested over 2 million RMB in environmental governance and protection during the reporting period[197]. - The company has established a comprehensive emergency response plan for environmental incidents, including regular emergency drills every six months[197]. Employee Management and Development - The company has a well-structured training system to enhance employee skills across various operational areas, including marketing, technology, and management[173]. - The company’s remuneration policy aims to align employee compensation with market standards and individual performance, ensuring competitive and fair pay[172]. - The company provides various employee benefits, including free meals and health check-ups, to enhance employee well-being[200].

关于举行 2022 年度网上业绩说明会的公告 证券代码：301080 证券简称：百普赛斯 公告编号：2023-012 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）《2022 年年度报 告全文》及其摘要已于 2023 年 4 月 26 日在巨潮资讯网（www.cninfo.com.cn） 进行了披露。 为便于广大投资者更深入全面地了解公司情况，公司定于 2023 年 5 月 15 日 （星期一）下午 15:00-17:00 在全景网举办 2022 年度业绩说明会，本次年度业绩 说明会将采用网络远程的方式举行，投资者可登陆"全景·路演天下" （http://rs.p5w.net）参与本次年度业绩说明会。 北京百普赛斯生物科技股份有限公司 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 11 日（星期四）17:00 前将关注的问题通过 http://rs.p5w.net 界面的提问 通道进行提问,公司 ...

证券代码：301080 证券简称：百普赛斯 编号：2022-004 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2021-001 | --- | --- | --- | |----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2021-002 | --- | --- | --- | |------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2021-003 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------- ...

证券代码：301080 证券简称：百普赛斯 北京百普赛斯生物科技股份有限公司 投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | |-------------------------|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...